Skip to main content
Neurodegenerative DiseaseDiagnostics and screeningHealthy volunteersBrain and nervesDrugPhase 2, Phase 3

What this study is

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).

What's being tested

  • 18F-AV-1451

    Intervention · DRUG

    The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit. The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.

Study details

Official title
Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease
Sponsor
University of Pennsylvania
Conditions
Neurodegenerative Disease
Enrolling
300 people
Starts
2016-08-23
Est. completion
2030-09
Design
Open-label, single group, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗